Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8
Shattuck Labs, a clinical-stage biotech company focusing on monoclonal and bispecific DR3-blocking antibodies, will hold an investor call on June 8 to present comprehensive Phase 1 clinical data for its lead candidate SL-325. The data includes safety, pharmacokinetics, and immunogenicity results. SL-325 is a potential first-in-class treatment targe…